Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epigenetic biomarker development for biologic response prediction in rheumatoid arthritis and psoriasis
NL-OMON56905Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of adalimumab, tocilizumab, abatacept, ustekinumab and secukinumab in rheumatoid arthritis (RA) and psoriasis (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Clinical efficacy in rheumatoid arthritis, Clinical efficacy in psoriasis and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriasis
Beyond the preview
Go deeper on NL-OMON56905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56905.